Clinical Research

At Arthritis and Rheumatic Diseases Specialties, we have a passion to provide the best care to our patients and improve their quality of life. We focus on the efficient diagnosis to start their way back to normal, satisfactory quality of life.

As leaders in our fields, we continually contribute to the development of new treatments and protocols by participating in clinical research. Clinical research is highly satisfactory for us, because it allows us to achieve two important goals: to help patients who need treatment options in the short term, and to contribute to the approval of better treatment protocols in the long term.

Right now, the following clinical studies are open. Please contact us by email at clinicalresearch@rheum-care.com or call us at 305-652-6676 to obtain more information on how to participate in these studies.

These links will take you to the description of the clinical trials being conducted currently in the office for Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE). Please contact us to see if you may qualify for any of these trials.

Ankylosing Spondylitis:

  • 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis (MEASURE4)
  • A Multicenter, Randomized, Double-blind, Placebo-Controlled 16 Week Studdy Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients with Radiographic Axial Spondyloarthritis
  • A Phase II Multicenter, Randomized, Double-blind, Placebo-Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subjects with Moderate to Severe Systemic Lupus Erythematosus
  • A 52-Week, Randomized, Double-blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus:

Rheumatoid Arthritis:

Psoriatic Arthritis:

Psoriatic Arthritis (PsA):

  • A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of secukinumab 300 mg and 150 mg in adult patients with active psoriatic arthritis after 16 weeks of treatment compared to placebo and to assess the safety, tolerability and efficacy up to 52 weeks

Osteoarthritis:

  • A Phase 3 Randomized, Double-blind, Active-Controlled, Multicenter Study of the Long-Term Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee

If you or anyone you know has been diagnosed with an autoimmune disorder including Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Ankylosing Spondylitis and Gout and may be interested in participating in a clinical research trial, please call the Research Department at 305-652-6676 to discuss the inclusion and exclusion criteria for participation in a clinical trial

Copyright © 2017 Arthritis & Rheumatic Disease Specialties | Nondiscrimination | Privacy Practices | Limited English Assistance Services